Global Immuno-Oncology Assays Market - 2025-2033
Global Immuno-Oncology Assays Market Size - Industry Trends & Outlook
The global immuno-oncology assays market size reached US$ 6.11 Billion in 2024 and is expected to reach US$ 17.96 Billion by 2033, growing at a CAGR of 12.8% during the forecast period 2025-2033.
Immuno-oncology assays are diagnostic tools that analyze immune responses and biomarkers to guide and monitor cancer immunotherapies.
The Immuno-oncology assays market is experiencing rapid growth, driven by the rising global cancer burden and increasing adoption of personalized medicine. These assays play a critical role in identifying and validating predictive biomarkers, monitoring immune responses, and guiding immunotherapy decisions.
Increasing developments in the immuno-oncology sector, advancements in technologies such as next-generation sequencing (NGS), multiplex immunohistochemistry (IHC), and spatial biology platforms, along with a surge in demand for companion diagnostics and targeted therapies, are driving the immuno-oncology market growth.
Expanding assay applications beyond common cancers like melanoma and colorectal cancer to rare and solid tumors, integration of AI for improved biomarker analysis, and growth in emerging markets where healthcare infrastructure is rapidly developing are expected to create lucrative opportunities for the market in the future.
North America is expected to remain the dominant region, supported by strong R&D activity, early regulatory approvals, and high adoption of immunotherapy. However, the Asia-Pacific region is anticipated to show the fastest growth due to increasing investments, rising cancer incidence, and growing awareness of advanced diagnostic tools. Overall, the market is poised for substantial expansion as precision oncology continues to reshape cancer care globally.
Global Immuno-Oncology Assays Market Dynamics: Drivers & Restraints
Increasing Developments in the Immuno-Oncology Sector are Expected to Drive the Immuno-Oncology Assays Market
Recent developments in immuno-oncology testing are significantly enhancing the prospects for more effective cancer diagnosis and treatment. A core focus of current innovation is on cancers with high prevalence, such as melanoma and colorectal cancer. Multiple companies and research institutions are introducing advanced diagnostic tools, grants, and platforms to support and accelerate this effort.
For example, in July 2024, Oxford BioDynamics announced a keynote presentation at the 14th World Summit for Clinical Biomarkers and Companion Diagnostics, highlighting the diagnostic, predictive, and prognostic capabilities of its EpiSwitch 3D genomics platform. This technology offers promising potential as a companion diagnostic assay.
Similarly, in February 2023, Agilent Technologies announced the integration of its xCelligence RTCA HT (real-time cell analysis high-throughput) platform with the BioTek BioSpa 8 Automated Incubator, enhancing workflow automation capabilities. This new combination of technologies was developed in response to market demands and offers innovative functionality for creating label-free high-throughput potency assays in the immuno-oncology field.
Further supporting innovation, Lunaphore launched the SPYRE Immuno-Oncology Grant Program in 2023 to help laboratories integrate spatial biology technologies into their immuno-oncology research. Meanwhile, Veracyte, Inc. shared data on its Immunoscore Immune Checkpoint (IC) assay, a tool designed to identify patients with metastatic colorectal cancer (mCRC), showcasing the expanding utility of immune profiling in treatment selection.
These advancements, along with increased investment in cancer research, growing awareness of diagnostic innovations, and the introduction of novel technologies, are collectively driving growth in the immuno-oncology assays market and offering new hope for personalized cancer therapy..
High Costs of Assays are Expected to Hinder the Immuno-Oncology Assays Market
The high cost of immuno-oncology assays is a significant barrier to market growth, particularly in low- and middle-income countries and smaller healthcare facilities. These assays often rely on advanced technologies such as multiplex immunohistochemistry, flow cytometry, next-generation sequencing (NGS), and spatial transcriptomics, all of which require expensive equipment, skilled personnel, and rigorous quality control.
For instance, automation systems and high-throughput platforms used in immuno-oncology diagnostics can cost between $40,000 and $60,000, excluding the ongoing expenses for reagents, software licenses, and data analysis infrastructure.
Global Immuno-Oncology Assays Market Segment Analysis
The global immuno-oncology assays market is segmented based on component type, cancer type, application, end user, and region.
Technology:
The immunoassay segment is expected to hold 32.79% of the global immuno-oncology assays market
The immunoassay segment is dominating the immuno-oncology assays market due to its precise and accurate ability to detect and treat cancer, especially before metastasis occurs. Immuno-oncology assays, such as immuno-cell killing assays, cell proliferation assays, and next-generation sequencing (NGS) assays, are gaining prominence for their specificity in identifying cancer at an early stage, thereby improving treatment outcomes. These assays are crucial in the growing field of precision medicine, where targeted therapies are designed based on individual cancer profiles.
For instance, in April 2023, Agilent Technologies Inc. launched the Agilent SureSelect Cancer CGP Assay, an NGS-based assay designed to profile a wide range of tumor types, further advancing precision immuno-oncology.
Similarly, in January 2022, Oncocyte partnered with Thermo Fisher Scientific to clinically validate the Oncomine Comprehensive Assay Plus, aiming to develop the Determalo test to predict responses to immuno-oncology therapies.
These advancements reflect the increasing role of immunoassays in enhancing the specificity and accuracy of cancer detection, driving the growth and dominance of this segment in the market.
Global Immuno-Oncology Assays Market Geographical Analysis
North America is expected to hold 42.1% of the global immuno-oncology assays market
North America is expected to dominate the global immuno-oncology assays market, primarily due to its advanced healthcare infrastructure, high prevalence of cancer, and strong research and development ecosystem. The region continues to lead the global immuno-oncology assays market, bolstered by recent regulatory approvals and product launches that underscore the region's commitment to advancing cancer diagnostics.
For instance, in August 2024, the FDA approved the SeCore CDx HLA A Sequencing System as a companion diagnostic for afamitresgene autoleucel. This approval highlights the growing integration of companion diagnostics in immuno-oncology, ensuring that therapies are matched to patients based on specific genetic markers.
These developments reflect North America's pivotal role in the evolution of immuno-oncology diagnostics, driven by robust regulatory support, significant research investments, and a strong infrastructure for clinical implementation.
Asia-Pacific is expected to hold 26.8% of the global immuno-oncology assays market
The Asia-Pacific region is projected to be the fastest-growing market in the global immuno-oncology landscape, driven by a rising cancer burden, increased government investment, and expanding research capabilities.
With nearly 50% of global cancer cases occurring in Asia, countries like China, India, and Japan are witnessing surging demand for advanced cancer diagnostics and treatments. Government support through national cancer control programs and investment in biotech innovation is accelerating research and facilitating regulatory approvals for novel immunotherapies.
Additionally, the region’s improving healthcare infrastructure and growing participation in clinical trials are contributing to the rapid adoption of immuno-oncology assays and therapies. Together, these factors position Asia-Pacific as the fastest-growing region in the global immuno-oncology market in the coming years.
Global Immuno-Oncology Assays Market Competitive Landscape
The top companies in the immuno-oncology assays market include Merck KGaA, Thermo Fisher Scientific Inc., Lunaphore Technologies SA., Eve Technologies., Vivia Biotech S.L, Illumina, Inc., Charles River Laboratories, Bio-Techne, Creative Biolabs, Miltenyi Biotec, Adipogen Life Sciences, among others.
Global Immuno-Oncology Assays Market Key Developments
Target Audience 2024
The global immuno-oncology assays market size reached US$ 6.11 Billion in 2024 and is expected to reach US$ 17.96 Billion by 2033, growing at a CAGR of 12.8% during the forecast period 2025-2033.
Immuno-oncology assays are diagnostic tools that analyze immune responses and biomarkers to guide and monitor cancer immunotherapies.
The Immuno-oncology assays market is experiencing rapid growth, driven by the rising global cancer burden and increasing adoption of personalized medicine. These assays play a critical role in identifying and validating predictive biomarkers, monitoring immune responses, and guiding immunotherapy decisions.
Increasing developments in the immuno-oncology sector, advancements in technologies such as next-generation sequencing (NGS), multiplex immunohistochemistry (IHC), and spatial biology platforms, along with a surge in demand for companion diagnostics and targeted therapies, are driving the immuno-oncology market growth.
Expanding assay applications beyond common cancers like melanoma and colorectal cancer to rare and solid tumors, integration of AI for improved biomarker analysis, and growth in emerging markets where healthcare infrastructure is rapidly developing are expected to create lucrative opportunities for the market in the future.
North America is expected to remain the dominant region, supported by strong R&D activity, early regulatory approvals, and high adoption of immunotherapy. However, the Asia-Pacific region is anticipated to show the fastest growth due to increasing investments, rising cancer incidence, and growing awareness of advanced diagnostic tools. Overall, the market is poised for substantial expansion as precision oncology continues to reshape cancer care globally.
Global Immuno-Oncology Assays Market Dynamics: Drivers & Restraints
Increasing Developments in the Immuno-Oncology Sector are Expected to Drive the Immuno-Oncology Assays Market
Recent developments in immuno-oncology testing are significantly enhancing the prospects for more effective cancer diagnosis and treatment. A core focus of current innovation is on cancers with high prevalence, such as melanoma and colorectal cancer. Multiple companies and research institutions are introducing advanced diagnostic tools, grants, and platforms to support and accelerate this effort.
For example, in July 2024, Oxford BioDynamics announced a keynote presentation at the 14th World Summit for Clinical Biomarkers and Companion Diagnostics, highlighting the diagnostic, predictive, and prognostic capabilities of its EpiSwitch 3D genomics platform. This technology offers promising potential as a companion diagnostic assay.
Similarly, in February 2023, Agilent Technologies announced the integration of its xCelligence RTCA HT (real-time cell analysis high-throughput) platform with the BioTek BioSpa 8 Automated Incubator, enhancing workflow automation capabilities. This new combination of technologies was developed in response to market demands and offers innovative functionality for creating label-free high-throughput potency assays in the immuno-oncology field.
Further supporting innovation, Lunaphore launched the SPYRE Immuno-Oncology Grant Program in 2023 to help laboratories integrate spatial biology technologies into their immuno-oncology research. Meanwhile, Veracyte, Inc. shared data on its Immunoscore Immune Checkpoint (IC) assay, a tool designed to identify patients with metastatic colorectal cancer (mCRC), showcasing the expanding utility of immune profiling in treatment selection.
These advancements, along with increased investment in cancer research, growing awareness of diagnostic innovations, and the introduction of novel technologies, are collectively driving growth in the immuno-oncology assays market and offering new hope for personalized cancer therapy..
High Costs of Assays are Expected to Hinder the Immuno-Oncology Assays Market
The high cost of immuno-oncology assays is a significant barrier to market growth, particularly in low- and middle-income countries and smaller healthcare facilities. These assays often rely on advanced technologies such as multiplex immunohistochemistry, flow cytometry, next-generation sequencing (NGS), and spatial transcriptomics, all of which require expensive equipment, skilled personnel, and rigorous quality control.
For instance, automation systems and high-throughput platforms used in immuno-oncology diagnostics can cost between $40,000 and $60,000, excluding the ongoing expenses for reagents, software licenses, and data analysis infrastructure.
Global Immuno-Oncology Assays Market Segment Analysis
The global immuno-oncology assays market is segmented based on component type, cancer type, application, end user, and region.
Technology:
The immunoassay segment is expected to hold 32.79% of the global immuno-oncology assays market
The immunoassay segment is dominating the immuno-oncology assays market due to its precise and accurate ability to detect and treat cancer, especially before metastasis occurs. Immuno-oncology assays, such as immuno-cell killing assays, cell proliferation assays, and next-generation sequencing (NGS) assays, are gaining prominence for their specificity in identifying cancer at an early stage, thereby improving treatment outcomes. These assays are crucial in the growing field of precision medicine, where targeted therapies are designed based on individual cancer profiles.
For instance, in April 2023, Agilent Technologies Inc. launched the Agilent SureSelect Cancer CGP Assay, an NGS-based assay designed to profile a wide range of tumor types, further advancing precision immuno-oncology.
Similarly, in January 2022, Oncocyte partnered with Thermo Fisher Scientific to clinically validate the Oncomine Comprehensive Assay Plus, aiming to develop the Determalo test to predict responses to immuno-oncology therapies.
These advancements reflect the increasing role of immunoassays in enhancing the specificity and accuracy of cancer detection, driving the growth and dominance of this segment in the market.
Global Immuno-Oncology Assays Market Geographical Analysis
North America is expected to hold 42.1% of the global immuno-oncology assays market
North America is expected to dominate the global immuno-oncology assays market, primarily due to its advanced healthcare infrastructure, high prevalence of cancer, and strong research and development ecosystem. The region continues to lead the global immuno-oncology assays market, bolstered by recent regulatory approvals and product launches that underscore the region's commitment to advancing cancer diagnostics.
For instance, in August 2024, the FDA approved the SeCore CDx HLA A Sequencing System as a companion diagnostic for afamitresgene autoleucel. This approval highlights the growing integration of companion diagnostics in immuno-oncology, ensuring that therapies are matched to patients based on specific genetic markers.
These developments reflect North America's pivotal role in the evolution of immuno-oncology diagnostics, driven by robust regulatory support, significant research investments, and a strong infrastructure for clinical implementation.
Asia-Pacific is expected to hold 26.8% of the global immuno-oncology assays market
The Asia-Pacific region is projected to be the fastest-growing market in the global immuno-oncology landscape, driven by a rising cancer burden, increased government investment, and expanding research capabilities.
With nearly 50% of global cancer cases occurring in Asia, countries like China, India, and Japan are witnessing surging demand for advanced cancer diagnostics and treatments. Government support through national cancer control programs and investment in biotech innovation is accelerating research and facilitating regulatory approvals for novel immunotherapies.
Additionally, the region’s improving healthcare infrastructure and growing participation in clinical trials are contributing to the rapid adoption of immuno-oncology assays and therapies. Together, these factors position Asia-Pacific as the fastest-growing region in the global immuno-oncology market in the coming years.
Global Immuno-Oncology Assays Market Competitive Landscape
The top companies in the immuno-oncology assays market include Merck KGaA, Thermo Fisher Scientific Inc., Lunaphore Technologies SA., Eve Technologies., Vivia Biotech S.L, Illumina, Inc., Charles River Laboratories, Bio-Techne, Creative Biolabs, Miltenyi Biotec, Adipogen Life Sciences, among others.
Global Immuno-Oncology Assays Market Key Developments
- On April 16, 2025, PODO Therapeutics announced that it will present its latest research at the American Association for Cancer Research (AACR) Annual Meeting 2025, scheduled for April 25-30 in the United States. The company will feature two poster presentations showcasing its innovative platform, which utilizes cancer organoids co-cultured with immune cells to more accurately predict individual patient responses to both immunotherapies and radiation treatments.
- In September 2024, BioMed X, a renowned German biomedical research institute, announced the launch of a new research team in collaboration with Ono Pharmaceutical Co., Ltd. from Japan. This partnership, the institute’s first with Ono Pharmaceutical, aims to explore the antitumor effects of neutrophils and develop next-generation immunotherapies.
- In July 2024, Tempus AI, Inc. announced that its multimodal immune profile score (IPS) algorithmic test is now available for research use only (RUO). IPS is the first offering of a larger immunotherapy-based portfolio being developed at Tempus to bring next-generation algorithmic diagnostics to the immuno-oncology space.
Target Audience 2024
- Manufacturers: Pharmaceutical, Medical Device, Biotech Companies, Contract Manufacturers, Distributors, Hospitals.
- Regulatory & Policy: Compliance Officers, Government, Health Economists, Market Access Specialists.
- Technology & Innovation: AI/Robotics Providers, R&D Professionals, Clinical Trial Managers, Pharmacovigilance Experts.
- Investors: Healthcare Investors, Venture Fund Investors, Pharma Marketing & Sales.
- Consulting & Advisory: Healthcare Consultants, Industry Associations, Analysts.
- Supply Chain: Distribution and Supply Chain Managers.
- Consumers & Advocacy: Patients, Advocacy Groups, Insurance Companies.
- Academic & Research: Academic Institutions.
1. MARKET INTRODUCTION AND SCOPE
1.1. Objectives of the Report
1.2. Report Coverage & Definitions
1.3. Report Scope
2. EXECUTIVE INSIGHTS AND KEY TAKEAWAYS
2.1. Market Highlights and Strategic Takeaways
2.2. Key Trends and Future Projections
2.3. Snippet by Type
2.4. Snippet by Treatment
2.5. Snippet by Route of Administration
2.6. Snippet by Region
3. DYNAMICS
3.1. Impacting Factors
3.1.1. Drivers
3.1.1.1. Increasing Developments in Immuno-Oncology Sector
3.1.1.2. Rising Prevalence of Cancer
3.1.2. Restraints
3.1.2.1. High Cost of Assays
3.1.2.2. Competition from Alternative Cancer Screening Methods
3.1.2.3. XX
3.1.3. Opportunity
3.1.3.1. Collaborations and Partnerships Among the Companies
3.1.3.2. XX
3.1.4. Impact Analysis
4. STRATEGIC INSIGHTS AND INDUSTRY OUTLOOK
4.1. Market Leaders and Pioneers
4.1.1. Emerging Pioneers and Prominent Players
4.1.2. Established Leaders with Largest Marketing Brand
4.1.3. Market Leaders with Established Products
4.2. Latest Developments and Breakthroughs
4.3. Regulatory and Reimbursement Landscape
4.3.1. North America
4.3.2. Europe
4.3.3. Asia Pacific
4.3.4. Latin America
4.3.5. Middle East & Africa
4.4. Porter’s Five Forces Analysis
4.5. Supply Chain Analysis
4.6. Patent Analysis
4.7. SWOT Analysis
4.8. Pipeline Analysis
4.9. Epidemiology Analysis
4.10. Unmet Needs and Gaps
4.11. Recommended Strategies for Market Entry and Expansion
4.12. Scenario Analysis: Best-Case, Base-Case, and Worst-Case Forecasts
4.13. Pricing Analysis and Price Dynamics
4.14. Key Opinion Leaders
5. IMMUNO-ONCOLOGY ASSAYS MARKET PRODUCT TYPE OUTLOOK
5.1. Introduction
5.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
5.1.2. Market Attractiveness Index, By Product Type
5.2. Instruments*
5.2.1. Introduction
5.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
5.3. Consumables
5.4. Software and Services
6. IMMUNO-ONCOLOGY ASSAYS MARKET ASSAY TYPE OUTLOOK
6.1. Introduction
6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Assay Type
6.1.2. Market Attractiveness Index, By Assay Type
6.2. Cell Proliferation Assays*
6.2.1. Introduction
6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
6.3. Cell Migration and Invasion Assays
6.4. Phagocytosis Assays
6.5. Immune Cell Killing Assays
6.6. Others
7. IMMUNO-ONCOLOGY ASSAYS MARKET TECHNOLOGY OUTLOOK
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
7.1.2. Market Attractiveness Index, By Technology
7.2. PCR*
7.2.1. Introduction
7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. NGS
7.4. Immunoassay
7.5. Flow Cytometry
7.6. Others
8. IMMUNO-ONCOLOGY ASSAYS MARKET INDICATION OUTLOOK
8.1. Introduction
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
8.1.2. Market Attractiveness Index, By Indication
8.2. Colorectal Cancer*
8.2.1. Introduction
8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Breast Cancer
8.4. Lung Cancer
8.5. Melanoma
8.6. Others
9. IMMUNO-ONCOLOGY ASSAYS MARKET END USER OUTLOOK
9.1. Introduction
9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
9.1.2. Market Attractiveness Index, By End User
9.2. Academic Institutes*
9.2.1. Introduction
9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
9.3. Research Organizations
9.4. Diagnostics Centers
9.5. Others
10. IMMUNO-ONCOLOGY ASSAYS MARKET, BY REGIONAL MARKET ANALYSIS AND GROWTH OPPORTUNITIES
10.1. Introduction
10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
10.1.2. Market Attractiveness Index, By Region
10.2. North America
10.2.1. Introduction
10.2.2. Key Region-Specific Dynamics
10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Assay Type
10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
10.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
10.2.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.2.8.1. U.S.
10.2.8.2. Canada
10.2.8.3. Mexico
10.3. Europe
10.3.1. Introduction
10.3.2. Key Region-Specific Dynamics
10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Assay Type
10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
10.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
10.3.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.3.8.1. Germany
10.3.8.2. UK
10.3.8.3. France
10.3.8.4. Spain
10.3.8.5. Italy
10.3.8.6. Rest of Europe
10.4. Asia-Pacific
10.4.1. Introduction
10.4.2. Key Region-Specific Dynamics
10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Assay Type
10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
10.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
10.4.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.4.8.1. China
10.4.8.2. India
10.4.8.3. Japan
10.4.8.4. South Korea
10.4.8.5. Rest of Asia-Pacific
10.5. South America
10.5.1. Introduction
10.5.2. Key Region-Specific Dynamics
10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Assay Type
10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
10.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
10.5.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.5.8.1. Brazil
10.5.8.2. Argentina
10.5.8.3. Rest of South America
10.6. Middle East and Africa
10.6.1. Introduction
10.6.2. Key Region-Specific Dynamics
10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Assay Type
10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
10.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
10.6.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
11. COMPETITIVE LANDSCAPE AND MARKET POSITIONING
11.1. Competitive Overview and Key Market Players
11.2. Market Share Analysis and Positioning Matrix
11.3. Strategic Partnerships, Mergers & Acquisitions
11.4. Key Developments in Product Portfolios and Innovations
11.5. Company Benchmarking
12. COMPANY PROFILES
Key Players
12.1. Merck KGaA*
12.1.1. Company Overview
12.1.2. Product Portfolio
12.1.2.1. Product Description
12.1.2.2. Product Key Performance Indicators (KPIs)
12.1.2.3. Historic and Forecasted Product Sales
12.1.2.4. Product Sales Volume
12.1.3. Financial Overview
12.1.3.1. Company Revenue
12.1.3.2. Geographical Revenue Shares
12.1.3.3. Revenue Forecasts
12.1.4. Key Developments
12.1.4.1. Mergers & Acquisitions
12.1.4.2. Key Product Development Activities
12.1.4.3. Regulatory Approvals, etc.
12.1.5. SWOT Analysis
12.2. Thermo Fisher Scientific Inc.
12.3. Lunaphore Technologies SA.
12.4. Eve Technologies.
12.5. Vivia Biotech S.L
12.6. Illumina, Inc.
12.7. Charles River Laboratories
12.8. Bio-Techne
12.9. Creative Biolabs
12.10. Miltenyi Biotec
12.11. Adipogen Life Sciences
LIST NOT EXHAUSTIVE
13. ASSUMPTION AND RESEARCH METHODOLOGY
13.1. Data Collection Methods
13.2. Data Triangulation
13.3. Forecasting Techniques
13.4. Data Verification and Validation
14. APPENDIX
14.1. About Us and Services
14.2. Contact Us
1.1. Objectives of the Report
1.2. Report Coverage & Definitions
1.3. Report Scope
2. EXECUTIVE INSIGHTS AND KEY TAKEAWAYS
2.1. Market Highlights and Strategic Takeaways
2.2. Key Trends and Future Projections
2.3. Snippet by Type
2.4. Snippet by Treatment
2.5. Snippet by Route of Administration
2.6. Snippet by Region
3. DYNAMICS
3.1. Impacting Factors
3.1.1. Drivers
3.1.1.1. Increasing Developments in Immuno-Oncology Sector
3.1.1.2. Rising Prevalence of Cancer
3.1.2. Restraints
3.1.2.1. High Cost of Assays
3.1.2.2. Competition from Alternative Cancer Screening Methods
3.1.2.3. XX
3.1.3. Opportunity
3.1.3.1. Collaborations and Partnerships Among the Companies
3.1.3.2. XX
3.1.4. Impact Analysis
4. STRATEGIC INSIGHTS AND INDUSTRY OUTLOOK
4.1. Market Leaders and Pioneers
4.1.1. Emerging Pioneers and Prominent Players
4.1.2. Established Leaders with Largest Marketing Brand
4.1.3. Market Leaders with Established Products
4.2. Latest Developments and Breakthroughs
4.3. Regulatory and Reimbursement Landscape
4.3.1. North America
4.3.2. Europe
4.3.3. Asia Pacific
4.3.4. Latin America
4.3.5. Middle East & Africa
4.4. Porter’s Five Forces Analysis
4.5. Supply Chain Analysis
4.6. Patent Analysis
4.7. SWOT Analysis
4.8. Pipeline Analysis
4.9. Epidemiology Analysis
4.10. Unmet Needs and Gaps
4.11. Recommended Strategies for Market Entry and Expansion
4.12. Scenario Analysis: Best-Case, Base-Case, and Worst-Case Forecasts
4.13. Pricing Analysis and Price Dynamics
4.14. Key Opinion Leaders
5. IMMUNO-ONCOLOGY ASSAYS MARKET PRODUCT TYPE OUTLOOK
5.1. Introduction
5.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
5.1.2. Market Attractiveness Index, By Product Type
5.2. Instruments*
5.2.1. Introduction
5.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
5.3. Consumables
5.4. Software and Services
6. IMMUNO-ONCOLOGY ASSAYS MARKET ASSAY TYPE OUTLOOK
6.1. Introduction
6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Assay Type
6.1.2. Market Attractiveness Index, By Assay Type
6.2. Cell Proliferation Assays*
6.2.1. Introduction
6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
6.3. Cell Migration and Invasion Assays
6.4. Phagocytosis Assays
6.5. Immune Cell Killing Assays
6.6. Others
7. IMMUNO-ONCOLOGY ASSAYS MARKET TECHNOLOGY OUTLOOK
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
7.1.2. Market Attractiveness Index, By Technology
7.2. PCR*
7.2.1. Introduction
7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. NGS
7.4. Immunoassay
7.5. Flow Cytometry
7.6. Others
8. IMMUNO-ONCOLOGY ASSAYS MARKET INDICATION OUTLOOK
8.1. Introduction
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
8.1.2. Market Attractiveness Index, By Indication
8.2. Colorectal Cancer*
8.2.1. Introduction
8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Breast Cancer
8.4. Lung Cancer
8.5. Melanoma
8.6. Others
9. IMMUNO-ONCOLOGY ASSAYS MARKET END USER OUTLOOK
9.1. Introduction
9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
9.1.2. Market Attractiveness Index, By End User
9.2. Academic Institutes*
9.2.1. Introduction
9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
9.3. Research Organizations
9.4. Diagnostics Centers
9.5. Others
10. IMMUNO-ONCOLOGY ASSAYS MARKET, BY REGIONAL MARKET ANALYSIS AND GROWTH OPPORTUNITIES
10.1. Introduction
10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
10.1.2. Market Attractiveness Index, By Region
10.2. North America
10.2.1. Introduction
10.2.2. Key Region-Specific Dynamics
10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Assay Type
10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
10.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
10.2.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.2.8.1. U.S.
10.2.8.2. Canada
10.2.8.3. Mexico
10.3. Europe
10.3.1. Introduction
10.3.2. Key Region-Specific Dynamics
10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Assay Type
10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
10.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
10.3.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.3.8.1. Germany
10.3.8.2. UK
10.3.8.3. France
10.3.8.4. Spain
10.3.8.5. Italy
10.3.8.6. Rest of Europe
10.4. Asia-Pacific
10.4.1. Introduction
10.4.2. Key Region-Specific Dynamics
10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Assay Type
10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
10.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
10.4.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.4.8.1. China
10.4.8.2. India
10.4.8.3. Japan
10.4.8.4. South Korea
10.4.8.5. Rest of Asia-Pacific
10.5. South America
10.5.1. Introduction
10.5.2. Key Region-Specific Dynamics
10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Assay Type
10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
10.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
10.5.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.5.8.1. Brazil
10.5.8.2. Argentina
10.5.8.3. Rest of South America
10.6. Middle East and Africa
10.6.1. Introduction
10.6.2. Key Region-Specific Dynamics
10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Assay Type
10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
10.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
10.6.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
11. COMPETITIVE LANDSCAPE AND MARKET POSITIONING
11.1. Competitive Overview and Key Market Players
11.2. Market Share Analysis and Positioning Matrix
11.3. Strategic Partnerships, Mergers & Acquisitions
11.4. Key Developments in Product Portfolios and Innovations
11.5. Company Benchmarking
12. COMPANY PROFILES
Key Players
12.1. Merck KGaA*
12.1.1. Company Overview
12.1.2. Product Portfolio
12.1.2.1. Product Description
12.1.2.2. Product Key Performance Indicators (KPIs)
12.1.2.3. Historic and Forecasted Product Sales
12.1.2.4. Product Sales Volume
12.1.3. Financial Overview
12.1.3.1. Company Revenue
12.1.3.2. Geographical Revenue Shares
12.1.3.3. Revenue Forecasts
12.1.4. Key Developments
12.1.4.1. Mergers & Acquisitions
12.1.4.2. Key Product Development Activities
12.1.4.3. Regulatory Approvals, etc.
12.1.5. SWOT Analysis
12.2. Thermo Fisher Scientific Inc.
12.3. Lunaphore Technologies SA.
12.4. Eve Technologies.
12.5. Vivia Biotech S.L
12.6. Illumina, Inc.
12.7. Charles River Laboratories
12.8. Bio-Techne
12.9. Creative Biolabs
12.10. Miltenyi Biotec
12.11. Adipogen Life Sciences
LIST NOT EXHAUSTIVE
13. ASSUMPTION AND RESEARCH METHODOLOGY
13.1. Data Collection Methods
13.2. Data Triangulation
13.3. Forecasting Techniques
13.4. Data Verification and Validation
14. APPENDIX
14.1. About Us and Services
14.2. Contact Us
LIST OF TABLES
Table 1 Global Immuno-Oncology Assays Market Value, By Product Type, 2025, 2029 & 2033 (US$ Million)
Table 2 Global Immuno-Oncology Assays Market Value, By Assay Type, 2025, 2029 & 2033 (US$ Million)
Table 3 Global Immuno-Oncology Assays Market Value, By Technology, 2025, 2029 & 2033 (US$ Million)
Table 4 Global Immuno-Oncology Assays Market Value, By Indication, 2025, 2029 & 2033 (US$ Million)
Table 5 Global Immuno-Oncology Assays Market Value, By End User, 2025, 2029 & 2033 (US$ Million)
Table 6 Global Immuno-Oncology Assays Market Value, By Region, 2025, 2029 & 2033 (US$ Million)
Table 7 Global Immuno-Oncology Assays Market Value, By Product Type, 2025, 2029 & 2033 (US$ Million)
Table 8 Global Immuno-Oncology Assays Market Value, By Product Type, 2022-2033 (US$ Million)
Table 9 Global Immuno-Oncology Assays Market Value, By Assay Type, 2025, 2029 & 2033 (US$ Million)
Table 10 Global Immuno-Oncology Assays Market Value, By Assay Type, 2022-2033 (US$ Million)
Table 11 Global Immuno-Oncology Assays Market Value, By Technology, 2025, 2029 & 2033 (US$ Million)
Table 12 Global Immuno-Oncology Assays Market Value, By Technology, 2022-2033 (US$ Million)
Table 13 Global Immuno-Oncology Assays Market Value, By Indication, 2025, 2029 & 2033 (US$ Million)
Table 14 Global Immuno-Oncology Assays Market Value, By Indication, 2022-2033 (US$ Million)
Table 15 Global Immuno-Oncology Assays Market Value, By End User, 2025, 2029 & 2033 (US$ Million)
Table 16 Global Immuno-Oncology Assays Market Value, By End User, 2022-2033 (US$ Million)
Table 17 Global Immuno-Oncology Assays Market Value, By Region, 2025, 2029 & 2033 (US$ Million)
Table 18 Global Immuno-Oncology Assays Market Value, By Region, 2022-2033 (US$ Million)
Table 19 North America Immuno-Oncology Assays Market Value, By Product Type, 2022-2033 (US$ Million)
Table 20 North America Immuno-Oncology Assays Market Value, By Assay Type, 2022-2033 (US$ Million)
Table 21 North America Immuno-Oncology Assays Market Value, By Technology, 2022-2033 (US$ Million)
Table 22 North America Immuno-Oncology Assays Market Value, By Indication, 2022-2033 (US$ Million)
Table 23 North America Immuno-Oncology Assays Market Value, By End User, 2022-2033 (US$ Million)
Table 24 North America Immuno-Oncology Assays Market Value, By Country, 2022-2033 (US$ Million)
Table 25 South America Immuno-Oncology Assays Market Value, By Product Type, 2022-2033 (US$ Million)
Table 26 South America Immuno-Oncology Assays Market Value, By Assay Type, 2022-2033 (US$ Million)
Table 27 South America Immuno-Oncology Assays Market Value, By Technology, 2022-2033 (US$ Million)
Table 28 South America Immuno-Oncology Assays Market Value, By Indication, 2022-2033 (US$ Million)
Table 29 South America Immuno-Oncology Assays Market Value, By End User, 2022-2033 (US$ Million)
Table 30 South America Immuno-Oncology Assays Market Value, By Country, 2022-2033 (US$ Million)
Table 31 Europe Immuno-Oncology Assays Market Value, By Product Type, 2022-2033 (US$ Million)
Table 32 Europe Immuno-Oncology Assays Market Value, By Assay Type, 2022-2033 (US$ Million)
Table 33 Europe Immuno-Oncology Assays Market Value, By Technology, 2022-2033 (US$ Million)
Table 34 Europe Immuno-Oncology Assays Market Value, By Indication, 2022-2033 (US$ Million)
Table 35 Europe Immuno-Oncology Assays Market Value, By End User, 2022-2033 (US$ Million)
Table 36 Europe Immuno-Oncology Assays Market Value, By Country, 2022-2033 (US$ Million)
Table 37 Asia-Pacific Immuno-Oncology Assays Market Value, By Product Type, 2022-2033 (US$ Million)
Table 38 Asia-Pacific Immuno-Oncology Assays Market Value, By Assay Type, 2022-2033 (US$ Million)
Table 39 Asia-Pacific Immuno-Oncology Assays Market Value, By Technology, 2022-2033 (US$ Million)
Table 40 Asia-Pacific Immuno-Oncology Assays Market Value, By Indication, 2022-2033 (US$ Million)
Table 41 Asia-Pacific Immuno-Oncology Assays Market Value, By End User, 2022-2033 (US$ Million)
Table 42 Asia-Pacific Immuno-Oncology Assays Market Value, By Country, 2022-2033 (US$ Million)
Table 43 Middle East and Africa Immuno-Oncology Assays Market Value, By Product Type, 2022-2033 (US$ Million)
Table 44 Middle East and Africa Immuno-Oncology Assays Market Value, By Assay Type, 2022-2033 (US$ Million)
Table 45 Middle East and Africa Immuno-Oncology Assays Market Value, By Technology, 2022-2033 (US$ Million)
Table 46 Middle East and Africa Immuno-Oncology Assays Market Value, By Indication, 2022-2033 (US$ Million)
Table 47 Middle East and Africa Immuno-Oncology Assays Market Value, By End User, 2022-2033 (US$ Million)
Table 48 Middle East and Africa Immuno-Oncology Assays Market Value, By Country, 2022-2033 (US$ Million)
Table 49 Merck KGaA: Overview
Table 50 Merck KGaA: Product Portfolio
Table 51 Merck KGaA: Key Developments
Table 52 Thermo Fisher Scientific Inc.: Overview
Table 53 Thermo Fisher Scientific Inc.: Product Portfolio
Table 54 Thermo Fisher Scientific Inc.: Key Developments
Table 55 Lunaphore Technologies SA.: Overview
Table 56 Lunaphore Technologies SA.: Product Portfolio
Table 57 Lunaphore Technologies SA.: Key Developments
Table 58 Eve Technologies: Overview
Table 59 Eve Technologies: Product Portfolio
Table 60 Eve Technologies: Key Developments
Table 61 Vivia Biotech S.L: Overview
Table 62 Vivia Biotech S.L: Product Portfolio
Table 63 Vivia Biotech S.L: Key Developments
Table 64 Illumina, Inc.: Overview
Table 65 Illumina, Inc.: Product Portfolio
Table 66 Illumina, Inc.: Key Developments
Table 67 Charles River Laboratories: Overview
Table 68 Charles River Laboratories: Product Portfolio
Table 69 Charles River Laboratories: Key Developments
Table 70 Bio-Techne: Overview
Table 71 Bio-Techne: Product Portfolio
Table 72 Bio-Techne: Key Developments
Table 73 Creative Biolabs: Overview
Table 74 Creative Biolabs: Product Portfolio
Table 75 Creative Biolabs: Key Developments
Table 76 Miltenyi Biotec: Overview
Table 77 Miltenyi Biotec: Product Portfolio
Table 78 Miltenyi Biotec: Key Developments
Table 79 Adipogen Life Sciences: Overview
Table 80 Adipogen Life Sciences: Product Portfolio
Table 81 Adipogen Life Sciences: Key Developments
Table 1 Global Immuno-Oncology Assays Market Value, By Product Type, 2025, 2029 & 2033 (US$ Million)
Table 2 Global Immuno-Oncology Assays Market Value, By Assay Type, 2025, 2029 & 2033 (US$ Million)
Table 3 Global Immuno-Oncology Assays Market Value, By Technology, 2025, 2029 & 2033 (US$ Million)
Table 4 Global Immuno-Oncology Assays Market Value, By Indication, 2025, 2029 & 2033 (US$ Million)
Table 5 Global Immuno-Oncology Assays Market Value, By End User, 2025, 2029 & 2033 (US$ Million)
Table 6 Global Immuno-Oncology Assays Market Value, By Region, 2025, 2029 & 2033 (US$ Million)
Table 7 Global Immuno-Oncology Assays Market Value, By Product Type, 2025, 2029 & 2033 (US$ Million)
Table 8 Global Immuno-Oncology Assays Market Value, By Product Type, 2022-2033 (US$ Million)
Table 9 Global Immuno-Oncology Assays Market Value, By Assay Type, 2025, 2029 & 2033 (US$ Million)
Table 10 Global Immuno-Oncology Assays Market Value, By Assay Type, 2022-2033 (US$ Million)
Table 11 Global Immuno-Oncology Assays Market Value, By Technology, 2025, 2029 & 2033 (US$ Million)
Table 12 Global Immuno-Oncology Assays Market Value, By Technology, 2022-2033 (US$ Million)
Table 13 Global Immuno-Oncology Assays Market Value, By Indication, 2025, 2029 & 2033 (US$ Million)
Table 14 Global Immuno-Oncology Assays Market Value, By Indication, 2022-2033 (US$ Million)
Table 15 Global Immuno-Oncology Assays Market Value, By End User, 2025, 2029 & 2033 (US$ Million)
Table 16 Global Immuno-Oncology Assays Market Value, By End User, 2022-2033 (US$ Million)
Table 17 Global Immuno-Oncology Assays Market Value, By Region, 2025, 2029 & 2033 (US$ Million)
Table 18 Global Immuno-Oncology Assays Market Value, By Region, 2022-2033 (US$ Million)
Table 19 North America Immuno-Oncology Assays Market Value, By Product Type, 2022-2033 (US$ Million)
Table 20 North America Immuno-Oncology Assays Market Value, By Assay Type, 2022-2033 (US$ Million)
Table 21 North America Immuno-Oncology Assays Market Value, By Technology, 2022-2033 (US$ Million)
Table 22 North America Immuno-Oncology Assays Market Value, By Indication, 2022-2033 (US$ Million)
Table 23 North America Immuno-Oncology Assays Market Value, By End User, 2022-2033 (US$ Million)
Table 24 North America Immuno-Oncology Assays Market Value, By Country, 2022-2033 (US$ Million)
Table 25 South America Immuno-Oncology Assays Market Value, By Product Type, 2022-2033 (US$ Million)
Table 26 South America Immuno-Oncology Assays Market Value, By Assay Type, 2022-2033 (US$ Million)
Table 27 South America Immuno-Oncology Assays Market Value, By Technology, 2022-2033 (US$ Million)
Table 28 South America Immuno-Oncology Assays Market Value, By Indication, 2022-2033 (US$ Million)
Table 29 South America Immuno-Oncology Assays Market Value, By End User, 2022-2033 (US$ Million)
Table 30 South America Immuno-Oncology Assays Market Value, By Country, 2022-2033 (US$ Million)
Table 31 Europe Immuno-Oncology Assays Market Value, By Product Type, 2022-2033 (US$ Million)
Table 32 Europe Immuno-Oncology Assays Market Value, By Assay Type, 2022-2033 (US$ Million)
Table 33 Europe Immuno-Oncology Assays Market Value, By Technology, 2022-2033 (US$ Million)
Table 34 Europe Immuno-Oncology Assays Market Value, By Indication, 2022-2033 (US$ Million)
Table 35 Europe Immuno-Oncology Assays Market Value, By End User, 2022-2033 (US$ Million)
Table 36 Europe Immuno-Oncology Assays Market Value, By Country, 2022-2033 (US$ Million)
Table 37 Asia-Pacific Immuno-Oncology Assays Market Value, By Product Type, 2022-2033 (US$ Million)
Table 38 Asia-Pacific Immuno-Oncology Assays Market Value, By Assay Type, 2022-2033 (US$ Million)
Table 39 Asia-Pacific Immuno-Oncology Assays Market Value, By Technology, 2022-2033 (US$ Million)
Table 40 Asia-Pacific Immuno-Oncology Assays Market Value, By Indication, 2022-2033 (US$ Million)
Table 41 Asia-Pacific Immuno-Oncology Assays Market Value, By End User, 2022-2033 (US$ Million)
Table 42 Asia-Pacific Immuno-Oncology Assays Market Value, By Country, 2022-2033 (US$ Million)
Table 43 Middle East and Africa Immuno-Oncology Assays Market Value, By Product Type, 2022-2033 (US$ Million)
Table 44 Middle East and Africa Immuno-Oncology Assays Market Value, By Assay Type, 2022-2033 (US$ Million)
Table 45 Middle East and Africa Immuno-Oncology Assays Market Value, By Technology, 2022-2033 (US$ Million)
Table 46 Middle East and Africa Immuno-Oncology Assays Market Value, By Indication, 2022-2033 (US$ Million)
Table 47 Middle East and Africa Immuno-Oncology Assays Market Value, By End User, 2022-2033 (US$ Million)
Table 48 Middle East and Africa Immuno-Oncology Assays Market Value, By Country, 2022-2033 (US$ Million)
Table 49 Merck KGaA: Overview
Table 50 Merck KGaA: Product Portfolio
Table 51 Merck KGaA: Key Developments
Table 52 Thermo Fisher Scientific Inc.: Overview
Table 53 Thermo Fisher Scientific Inc.: Product Portfolio
Table 54 Thermo Fisher Scientific Inc.: Key Developments
Table 55 Lunaphore Technologies SA.: Overview
Table 56 Lunaphore Technologies SA.: Product Portfolio
Table 57 Lunaphore Technologies SA.: Key Developments
Table 58 Eve Technologies: Overview
Table 59 Eve Technologies: Product Portfolio
Table 60 Eve Technologies: Key Developments
Table 61 Vivia Biotech S.L: Overview
Table 62 Vivia Biotech S.L: Product Portfolio
Table 63 Vivia Biotech S.L: Key Developments
Table 64 Illumina, Inc.: Overview
Table 65 Illumina, Inc.: Product Portfolio
Table 66 Illumina, Inc.: Key Developments
Table 67 Charles River Laboratories: Overview
Table 68 Charles River Laboratories: Product Portfolio
Table 69 Charles River Laboratories: Key Developments
Table 70 Bio-Techne: Overview
Table 71 Bio-Techne: Product Portfolio
Table 72 Bio-Techne: Key Developments
Table 73 Creative Biolabs: Overview
Table 74 Creative Biolabs: Product Portfolio
Table 75 Creative Biolabs: Key Developments
Table 76 Miltenyi Biotec: Overview
Table 77 Miltenyi Biotec: Product Portfolio
Table 78 Miltenyi Biotec: Key Developments
Table 79 Adipogen Life Sciences: Overview
Table 80 Adipogen Life Sciences: Product Portfolio
Table 81 Adipogen Life Sciences: Key Developments
LIST OF FIGURES
Figure 1 Global Immuno-Oncology Assays Market Value, 2022-2033 (US$ Million)
Figure 2 Global Immuno-Oncology Assays Market Share, By Product Type, 2024 & 2033 (%)
Figure 3 Global Immuno-Oncology Assays Market Share, By Assay Type, 2024 & 2033 (%)
Figure 4 Global Immuno-Oncology Assays Market Share, By Technology, 2024 & 2033 (%)
Figure 5 Global Immuno-Oncology Assays Market Share, By Indication, 2024 & 2033 (%)
Figure 6 Global Immuno-Oncology Assays Market Share, By End User, 2024 & 2033 (%)
Figure 7 Global Immuno-Oncology Assays Market Share, By Region, 2024 & 2033 (%)
Figure 8 Global Immuno-Oncology Assays Market Y-o-Y Growth, By Product Type, 2023-2033 (%)
Figure 9 Instruments Immuno-Oncology Assays Market Value, 2022-2033 (US$ Million)
Figure 10 Consumables Immuno-Oncology Assays Market Value, 2022-2033 (US$ Million)
Figure 11 Software and Services Immuno-Oncology Assays Market Value, 2022-2033 (US$ Million)
Figure 12 Global Immuno-Oncology Assays Market Y-o-Y Growth, By Assay Type, 2023-2033 (%)
Figure 13 Cell Proliferation Assays Assay Type in Global Immuno-Oncology Assays Market Value, 2022-2033 (US$ Million)
Figure 14 Cell Migration and Invasion Assays Assay Type in Global Immuno-Oncology Assays Market Value, 2022-2033 (US$ Million)
Figure 15 Phagocytosis Assays Assay Type in Global Immuno-Oncology Assays Market Value, 2022-2033 (US$ Million)
Figure 16 Immune Cell Killing Assays Assay Type in Global Immuno-Oncology Assays Market Value, 2022-2033 (US$ Million)
Figure 17 Others Assay Type in Global Immuno-Oncology Assays Market Value, 2022-2033 (US$ Million)
Figure 18 Global Immuno-Oncology Assays Market Y-o-Y Growth, By Technology, 2023-2033 (%)
Figure 19 PCR Technology in Global Immuno-Oncology Assays Market Value, 2022-2033 (US$ Million)
Figure 20 NGS Technology in Global Immuno-Oncology Assays Market Value, 2022-2033 (US$ Million)
Figure 21 Immunoassay Technology in Global Immuno-Oncology Assays Market Value, 2022-2033 (US$ Million)
Figure 22 Flow Cytometry Technology in Global Immuno-Oncology Assays Market Value, 2022-2033 (US$ Million)
Figure 23 Others Technology in Global Immuno-Oncology Assays Market Value, 2022-2033 (US$ Million)
Figure 24 Global Immuno-Oncology Assays Market Y-o-Y Growth, By Indication, 2023-2033 (%)
Figure 25 Colorectal Cancer Indication in Global Immuno-Oncology Assays Market Value, 2022-2033 (US$ Million)
Figure 26 Breast Cancer Indication in Global Immuno-Oncology Assays Market Value, 2022-2033 (US$ Million)
Figure 27 Lung Cancer Indication in Global Immuno-Oncology Assays Market Value, 2022-2033 (US$ Million)
Figure 28 Melanoma Indication in Global Immuno-Oncology Assays Market Value, 2022-2033 (US$ Million)
Figure 29 Others Indication in Global Immuno-Oncology Assays Market Value, 2022-2033 (US$ Million)
Figure 30 Global Immuno-Oncology Assays Market Y-o-Y Growth, By End User, 2023-2033 (%)
Figure 31 Academic Institutes End User in Global Immuno-Oncology Assays Market Value, 2022-2033 (US$ Million)
Figure 32 Research Organizations End User in Global Immuno-Oncology Assays Market Value, 2022-2033 (US$ Million)
Figure 33 Diagnostics Centers End User in Global Immuno-Oncology Assays Market Value, 2022-2033 (US$ Million)
Figure 34 Others End User in Global Immuno-Oncology Assays Market Value, 2022-2033 (US$ Million)
Figure 35 Global Immuno-Oncology Assays Market Y-o-Y Growth, By Region, 2023-2033 (%)
Figure 36 North America Immuno-Oncology Assays Market Value, 2022-2033 (US$ Million)
Figure 37 North America Immuno-Oncology Assays Market Share, By Product Type, 2024 & 2033 (%)
Figure 38 North America Immuno-Oncology Assays Market Share, By Assay Type, 2024 & 2033 (%)
Figure 39 North America Immuno-Oncology Assays Market Share, By Technology, 2024 & 2033 (%)
Figure 40 North America Immuno-Oncology Assays Market Share, By Indication, 2024 & 2033 (%)
Figure 41 North America Immuno-Oncology Assays Market Share, By End User, 2024 & 2033 (%)
Figure 42 North America Immuno-Oncology Assays Market Share, By Country, 2024 & 2033 (%)
Figure 43 South America Immuno-Oncology Assays Market Value, 2022-2033 (US$ Million)
Figure 44 South America Immuno-Oncology Assays Market Share, By Product Type, 2024 & 2033 (%)
Figure 45 South America Immuno-Oncology Assays Market Share, By Assay Type, 2024 & 2033 (%)
Figure 46 South America Immuno-Oncology Assays Market Share, By Technology, 2024 & 2033 (%)
Figure 47 South America Immuno-Oncology Assays Market Share, By Indication, 2024 & 2033 (%)
Figure 48 South America Immuno-Oncology Assays Market Share, By End User, 2024 & 2033 (%)
Figure 49 South America Immuno-Oncology Assays Market Share, By Country, 2024 & 2033 (%)
Figure 50 Europe Immuno-Oncology Assays Market Value, 2022-2033 (US$ Million)
Figure 51 Europe Immuno-Oncology Assays Market Share, By Product Type, 2024 & 2033 (%)
Figure 52 Europe Immuno-Oncology Assays Market Share, By Assay Type, 2024 & 2033 (%)
Figure 53 Europe Immuno-Oncology Assays Market Share, By Technology, 2024 & 2033 (%)
Figure 54 Europe Immuno-Oncology Assays Market Share, By Indication, 2024 & 2033 (%)
Figure 55 Europe Immuno-Oncology Assays Market Share, By End User, 2024 & 2033 (%)
Figure 56 Europe Immuno-Oncology Assays Market Share, By Country, 2024 & 2033 (%)
Figure 57 Asia-Pacific Immuno-Oncology Assays Market Value, 2022-2033 (US$ Million)
Figure 58 Asia-Pacific Immuno-Oncology Assays Market Share, By Product Type, 2024 & 2033 (%)
Figure 59 Asia-Pacific Immuno-Oncology Assays Market Share, By Assay Type, 2024 & 2033 (%)
Figure 60 Asia-Pacific Immuno-Oncology Assays Market Share, By Technology, 2024 & 2033 (%)
Figure 61 Asia-Pacific Immuno-Oncology Assays Market Share, By Indication, 2024 & 2033 (%)
Figure 62 Asia-Pacific Immuno-Oncology Assays Market Share, By End User, 2024 & 2033 (%)
Figure 63 Asia-Pacific Immuno-Oncology Assays Market Share, By Country, 2024 & 2033 (%)
Figure 64 Middle East and Africa Immuno-Oncology Assays Market Value, 2022-2033 (US$ Million)
Figure 65 Middle East and Africa Immuno-Oncology Assays Market Share, By Product Type, 2024 & 2033 (%)
Figure 66 Middle East and Africa Immuno-Oncology Assays Market Share, By Assay Type, 2024 & 2033 (%)
Figure 67 Middle East and Africa Immuno-Oncology Assays Market Share, By Technology, 2024 & 2033 (%)
Figure 68 Middle East and Africa Immuno-Oncology Assays Market Share, By Indication, 2024 & 2033 (%)
Figure 69 Middle East and Africa Immuno-Oncology Assays Market Share, By End User, 2024 & 2033 (%)
Figure 70 Merck KGaA: Financials
Figure 71 Thermo Fisher Scientific Inc.: Financials
Figure 72 Lunaphore Technologies SA.: Financials
Figure 73 Eve Technologies: Financials
Figure 74 Vivia Biotech S.L: Financials
Figure 75 Illumina, Inc.: Financials
Figure 76 Charles River Laboratories: Financials
Figure 77 Bio-Techne: Financials
Figure 78 Creative Biolabs: Financials
Figure 79 Miltenyi Biotec: Financials
Figure 80 Adipogen Life Sciences: Financials
Figure 1 Global Immuno-Oncology Assays Market Value, 2022-2033 (US$ Million)
Figure 2 Global Immuno-Oncology Assays Market Share, By Product Type, 2024 & 2033 (%)
Figure 3 Global Immuno-Oncology Assays Market Share, By Assay Type, 2024 & 2033 (%)
Figure 4 Global Immuno-Oncology Assays Market Share, By Technology, 2024 & 2033 (%)
Figure 5 Global Immuno-Oncology Assays Market Share, By Indication, 2024 & 2033 (%)
Figure 6 Global Immuno-Oncology Assays Market Share, By End User, 2024 & 2033 (%)
Figure 7 Global Immuno-Oncology Assays Market Share, By Region, 2024 & 2033 (%)
Figure 8 Global Immuno-Oncology Assays Market Y-o-Y Growth, By Product Type, 2023-2033 (%)
Figure 9 Instruments Immuno-Oncology Assays Market Value, 2022-2033 (US$ Million)
Figure 10 Consumables Immuno-Oncology Assays Market Value, 2022-2033 (US$ Million)
Figure 11 Software and Services Immuno-Oncology Assays Market Value, 2022-2033 (US$ Million)
Figure 12 Global Immuno-Oncology Assays Market Y-o-Y Growth, By Assay Type, 2023-2033 (%)
Figure 13 Cell Proliferation Assays Assay Type in Global Immuno-Oncology Assays Market Value, 2022-2033 (US$ Million)
Figure 14 Cell Migration and Invasion Assays Assay Type in Global Immuno-Oncology Assays Market Value, 2022-2033 (US$ Million)
Figure 15 Phagocytosis Assays Assay Type in Global Immuno-Oncology Assays Market Value, 2022-2033 (US$ Million)
Figure 16 Immune Cell Killing Assays Assay Type in Global Immuno-Oncology Assays Market Value, 2022-2033 (US$ Million)
Figure 17 Others Assay Type in Global Immuno-Oncology Assays Market Value, 2022-2033 (US$ Million)
Figure 18 Global Immuno-Oncology Assays Market Y-o-Y Growth, By Technology, 2023-2033 (%)
Figure 19 PCR Technology in Global Immuno-Oncology Assays Market Value, 2022-2033 (US$ Million)
Figure 20 NGS Technology in Global Immuno-Oncology Assays Market Value, 2022-2033 (US$ Million)
Figure 21 Immunoassay Technology in Global Immuno-Oncology Assays Market Value, 2022-2033 (US$ Million)
Figure 22 Flow Cytometry Technology in Global Immuno-Oncology Assays Market Value, 2022-2033 (US$ Million)
Figure 23 Others Technology in Global Immuno-Oncology Assays Market Value, 2022-2033 (US$ Million)
Figure 24 Global Immuno-Oncology Assays Market Y-o-Y Growth, By Indication, 2023-2033 (%)
Figure 25 Colorectal Cancer Indication in Global Immuno-Oncology Assays Market Value, 2022-2033 (US$ Million)
Figure 26 Breast Cancer Indication in Global Immuno-Oncology Assays Market Value, 2022-2033 (US$ Million)
Figure 27 Lung Cancer Indication in Global Immuno-Oncology Assays Market Value, 2022-2033 (US$ Million)
Figure 28 Melanoma Indication in Global Immuno-Oncology Assays Market Value, 2022-2033 (US$ Million)
Figure 29 Others Indication in Global Immuno-Oncology Assays Market Value, 2022-2033 (US$ Million)
Figure 30 Global Immuno-Oncology Assays Market Y-o-Y Growth, By End User, 2023-2033 (%)
Figure 31 Academic Institutes End User in Global Immuno-Oncology Assays Market Value, 2022-2033 (US$ Million)
Figure 32 Research Organizations End User in Global Immuno-Oncology Assays Market Value, 2022-2033 (US$ Million)
Figure 33 Diagnostics Centers End User in Global Immuno-Oncology Assays Market Value, 2022-2033 (US$ Million)
Figure 34 Others End User in Global Immuno-Oncology Assays Market Value, 2022-2033 (US$ Million)
Figure 35 Global Immuno-Oncology Assays Market Y-o-Y Growth, By Region, 2023-2033 (%)
Figure 36 North America Immuno-Oncology Assays Market Value, 2022-2033 (US$ Million)
Figure 37 North America Immuno-Oncology Assays Market Share, By Product Type, 2024 & 2033 (%)
Figure 38 North America Immuno-Oncology Assays Market Share, By Assay Type, 2024 & 2033 (%)
Figure 39 North America Immuno-Oncology Assays Market Share, By Technology, 2024 & 2033 (%)
Figure 40 North America Immuno-Oncology Assays Market Share, By Indication, 2024 & 2033 (%)
Figure 41 North America Immuno-Oncology Assays Market Share, By End User, 2024 & 2033 (%)
Figure 42 North America Immuno-Oncology Assays Market Share, By Country, 2024 & 2033 (%)
Figure 43 South America Immuno-Oncology Assays Market Value, 2022-2033 (US$ Million)
Figure 44 South America Immuno-Oncology Assays Market Share, By Product Type, 2024 & 2033 (%)
Figure 45 South America Immuno-Oncology Assays Market Share, By Assay Type, 2024 & 2033 (%)
Figure 46 South America Immuno-Oncology Assays Market Share, By Technology, 2024 & 2033 (%)
Figure 47 South America Immuno-Oncology Assays Market Share, By Indication, 2024 & 2033 (%)
Figure 48 South America Immuno-Oncology Assays Market Share, By End User, 2024 & 2033 (%)
Figure 49 South America Immuno-Oncology Assays Market Share, By Country, 2024 & 2033 (%)
Figure 50 Europe Immuno-Oncology Assays Market Value, 2022-2033 (US$ Million)
Figure 51 Europe Immuno-Oncology Assays Market Share, By Product Type, 2024 & 2033 (%)
Figure 52 Europe Immuno-Oncology Assays Market Share, By Assay Type, 2024 & 2033 (%)
Figure 53 Europe Immuno-Oncology Assays Market Share, By Technology, 2024 & 2033 (%)
Figure 54 Europe Immuno-Oncology Assays Market Share, By Indication, 2024 & 2033 (%)
Figure 55 Europe Immuno-Oncology Assays Market Share, By End User, 2024 & 2033 (%)
Figure 56 Europe Immuno-Oncology Assays Market Share, By Country, 2024 & 2033 (%)
Figure 57 Asia-Pacific Immuno-Oncology Assays Market Value, 2022-2033 (US$ Million)
Figure 58 Asia-Pacific Immuno-Oncology Assays Market Share, By Product Type, 2024 & 2033 (%)
Figure 59 Asia-Pacific Immuno-Oncology Assays Market Share, By Assay Type, 2024 & 2033 (%)
Figure 60 Asia-Pacific Immuno-Oncology Assays Market Share, By Technology, 2024 & 2033 (%)
Figure 61 Asia-Pacific Immuno-Oncology Assays Market Share, By Indication, 2024 & 2033 (%)
Figure 62 Asia-Pacific Immuno-Oncology Assays Market Share, By End User, 2024 & 2033 (%)
Figure 63 Asia-Pacific Immuno-Oncology Assays Market Share, By Country, 2024 & 2033 (%)
Figure 64 Middle East and Africa Immuno-Oncology Assays Market Value, 2022-2033 (US$ Million)
Figure 65 Middle East and Africa Immuno-Oncology Assays Market Share, By Product Type, 2024 & 2033 (%)
Figure 66 Middle East and Africa Immuno-Oncology Assays Market Share, By Assay Type, 2024 & 2033 (%)
Figure 67 Middle East and Africa Immuno-Oncology Assays Market Share, By Technology, 2024 & 2033 (%)
Figure 68 Middle East and Africa Immuno-Oncology Assays Market Share, By Indication, 2024 & 2033 (%)
Figure 69 Middle East and Africa Immuno-Oncology Assays Market Share, By End User, 2024 & 2033 (%)
Figure 70 Merck KGaA: Financials
Figure 71 Thermo Fisher Scientific Inc.: Financials
Figure 72 Lunaphore Technologies SA.: Financials
Figure 73 Eve Technologies: Financials
Figure 74 Vivia Biotech S.L: Financials
Figure 75 Illumina, Inc.: Financials
Figure 76 Charles River Laboratories: Financials
Figure 77 Bio-Techne: Financials
Figure 78 Creative Biolabs: Financials
Figure 79 Miltenyi Biotec: Financials
Figure 80 Adipogen Life Sciences: Financials
